David Baudry
A5037386534- Psoriasis: Treatment and Pathogenesis
- Asthma and respiratory diseases
- Dermatology and Skin Diseases
- T-cell and B-cell Immunology
- melanin and skin pigmentation
- Renal and related cancers
- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
- Hair Growth and Disorders
- Cytokine Signaling Pathways and Interactions
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- IL-33, ST2, and ILC Pathways
- Acne and Rosacea Treatments and Effects
- Cancer-related Molecular Pathways
- Medical and Biological Ozone Research
- Drug-Induced Adverse Reactions
- Autoimmune Bullous Skin Diseases
- Immune Cell Function and Interaction
- Renal cell carcinoma treatment
- Heparin-Induced Thrombocytopenia and Thrombosis
- Health Systems, Economic Evaluations, Quality of Life
- RNA regulation and disease
King's College London
2014-2025
University of Glasgow
2020-2024
Guy's and St Thomas' NHS Foundation Trust
2021-2023
Guy's Hospital
2019
St John's Hospital
2018
Université Paris Cité
2000-2001
Hôpital Necker-Enfants Malades
2000-2001
Inserm
2000-2001
Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses BNT162b2 (Pfizer-BioNTech) in patients taking methotrexate commonly used targeted biological therapies, compared with healthy controls. Given the roll-out of extended interval vaccination programmes maximise population coverage, we present findings after first dose.In this cohort study, recruited...
Frontal fibrosing alopecia (FFA) is a recently described inflammatory and scarring type of hair loss affecting almost exclusively women. Despite dramatic recent increase in incidence the aetiopathogenesis FFA remains unknown. We undertake genome-wide association studies females from UK cohort, comprising 844 cases 3,760 controls, Spanish cohort 172 385 perform statistical meta-analysis. observe significant with at four genomic loci: 2p22.2, 6p21.1, 8q24.22 15q2.1. Within 6p21.1 locus,...
Biologics have transformed management of inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by circulating drug levels has been proposed. We aimed to determine the real-world clinical utility therapeutic monitoring in psoriasis. Within a multicenter (n = 60) prospective observational cohort, 544 psoriasis patients were included who receiving adalimumab monotherapy had at least one serum sample Psoriasis Area Severity Index (PASI) score available within...
The identification of disease alleles underlying human autoinflammatory diseases can provide important insights into the mechanisms that maintain neutrophil homeostasis. Here, we focused our attention on generalized pustular psoriasis (GPP), a potentially life-threatening disorder presenting with cutaneous and systemic neutrophilia. Following whole-exome sequencing 19 unrelated affected individuals, identified subject harboring homozygous splice-site mutation (c.2031-2A>C) in MPO. This...
BackgroundCOVID-19 vaccines have robust immunogenicity in the general population. However, data for individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains scarce. Our previously published cohort study showed that methotrexate, but not targeted biologics, impaired functional humoral immunity to a single dose of COVID-19 vaccine BNT162b2 (Pfizer-BioNTech), whereas cellular responses were similar. Here, we aimed assess immune following second...
Abstract Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to not fully explained variation at robustly risk loci. To move towards saturation map susceptibility we meta-analysed 18 GWAS comprising 36,466 cases and 458,078 controls 109 distinct loci, 45 that been previously reported. These include variants loci in which...
Rising numbers of individuals receiving psoriasis biologics achieve clear/nearly clear skin (disease control). Trial data indicate some maintain control with lower doses, especially those higher serum drug concentrations. This indicates potential for Model-Informed Precision Dosing (MIPD), an advanced therapeutic monitoring technique, in guiding dose minimisation. We developed, validated, and user-tested a precision dosing dashboard. applied MIPD approach leveraging Bayesian estimation to...
High-cost biologic therapies have transformed the management of immune-mediated inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by measurement circulating drug levels has been shown to be effective in various settings. However, limited evidence exists for this approach with interleukin 12 23 inhibitor ustekinumab.To evaluate clinical utility therapeutic monitoring ustekinumab patients psoriasis.A prospective observational cohort 491 adults psoriasis was...
BackgroundFew studies have explored the immunology and genetic risk of paradoxical eczema occurring as an adverse event biologic therapy in patients with psoriasis.ObjectivesWe sought to describe systemic inflammatory signature using proteomics explore whether this is genetically mediated.MethodsThis study used Olink Target 96 Inflammation panel on 256 serum samples from 71 psoriasis eczema, 75 controls identify differentially expressed proteins enriched gene sets. Case 1 or more time points...
The identification of robust endotypes-disease subgroups clinical relevance-is fundamental to stratified medicine. We hypothesized that HLA-C∗06:02 status, the major genetic determinant psoriasis, defines a psoriasis endotype relevance. Using two United Kingdom-based cross-sectional datasets-an observational severe-psoriasis study (Biomarkers Systemic Treatment Outcomes in Psoriasis; n = 3,767) and large population-based bioresource (UK Biobank, including 5,519 individuals with psoriasis)-we...
Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation drug exposure. Real‐world psoriasis data were used develop a pharmacokinetic/pharmacodynamic (PK/PD) model the first‐line therapeutic antibody ustekinumab. The impact of differing dosing strategies on was explored. Data collected from UK prospective multicenter observational cohort (491 patients ustekinumab monotherapy, levels, and anti‐drug measurements 797 serum samples,...
Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), important cause treatment failure. The most widely used across immune-mediated diseases is adalimumab, a tumor necrosis factor inhibitor. This study aimed to identify genetic variants that contribute ADA against thereby influencing In patients with psoriasis on their first course in whom serum had been evaluated 6-36 months after starting treatment, we...
Abstract The use of biological drugs targeting the interleukin (IL)-23/IL-17 axis has greatly improved outcomes in people with psoriasis, an increasing number achieving clear skin (‘remission’). However, early mechanisms biologic-induced psoriasis resolution are yet to be fully explored. Longitudinal sampling resolving disease tissue provides opportunity uncover dynamic cellular and molecular events triggered by these powerful treatments. Identifying sequence key drivers underpinning may...